Table 4. Number of high-risk (HR)-HPV genotype infections within histological diagnoses in HPV screened positive women and most common HR-HPV co-infections.
| ≤CIN1 | CIN2 | CIN3 | Cancer | |
|---|---|---|---|---|
| n (% 95%IC) | n (% 95%IC) | n (% 95%IC) | n (% 95%IC) | |
| Number of HR-HPV genotypes | ||||
| None | 188 (22% 19.3–24.9) | 22 (18.2% 11.8–26.2) | 9 (4.6% 2.1–8.6) | 2 (2.4% 0.3–8.4) |
| One | 488 (57.1% 53.7–60.5) | 69 (57% 47.7–66) | 140 (72.2% 65.3–78.3) | 76 (91.6% 83.4–96.5) |
| Two | 138 (16.2% 13.8–18.8) | 24 (19.8% 13.1–28.1) | 36 (18.6% 13.3–24.8) | 4 (4.8% 1.3–11.9) |
| Three or more | 40 (4.7% 3.4–6.3) | 6 (5% 1.8–10.5) | 9 (4.6% 2.1–8.6) | 1 (1.2% 0–6.5) |
| Total number of women | 854 (100%) | 121 (100%) | 194 (100%) | 83 (100%) |
| HR-HPV genotypes pairs | ||||
| HPV16 and HPV31 | 10 (1.2% 0.6–2.1) | 3 (2.5% 0.5–7.1) | 4 (2.1% 0.6–5.2) | 0 (0% 0–4.3) |
| HPV16 and HPV52 | 5 (0.6% 0.2–1.4) | 1 (0.8% 0–4.5) | 7 (3.6% 1.5–7.3) | 0 (0% 0–4.3) |
| HPV52 and HPV18 | 7 (0.8% 0.3–1.7) | 2 (1.7% 0.2–5.8) | 3 (1.5% 0.3–4.5) | 0 (0% 0–4.3) |
| HPV52 and HPV31 | 8 (0.9% 0.4–1.8) | 3 (2.5% 0.5–7.1) | 1 (0.5% 0–2.8) | 0 (0% 0–4.3) |
| HPV16 and HPV39 | 6 (0.7% 0.3–1.5) | 1 (0.8% 0–4.5) | 4 (2.1% 0.6–5.2) | 0 (0% 0–4.3) |
| HPV16 and HPV18 | 4 (0.5% 0.1–1.2) | 1 (0.8% 0–4.5) | 4 (2.1% 0.6–5.2) | 1 (1.2% 0–6.5) |
| HPV16 and HPV66 | 7 (0.8% 0.3–1.7) | 0 (0% 0–3) | 2 (1% 0.1–3.7) | 1 (1.2% 0–6.5) |
| HPV52 and HPV56 | 8 (0.9% 0.4–1.8) | 0 (0% 0–3) | 2 (1% 0.1–3.7) | 0 (0% 0–4.3) |
| HPV16 and HPV58 | 5 (0.6% 0.2–1.4) | 1 (0.8% 0–4.5) | 2 (1% 0.1–3.7) | 1 (1.2% 0–6.5) |
| HPV16 and HPV59 | 5 (0.6% 0.2–1.4) | 2 (1.7% 0.2–5.8) | 2 (1% 0.1–3.7) | 0 (0% 0–4.3) |
Number of positive participants, prevalence (%) and 95% confidence intervals shown by the number of genotypes detected (none, one, two or three or more; mutually exclusive groups). Computations for the ten most frequent pairs of genotypes detected also shown.